Tolbutamide is a first-generation sulphonylurea historically used to manage type 2 diabetes, though it is no longer routinely available in the UK. Incretin hormones—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)—are naturally occurring peptides that enhance insulin secretion in response to food intake. A common question is whether tolbutamide increases the duration of action of incretins. The evidence is clear: there is no established pharmacological mechanism by which sulphonylureas, including tolbutamide, directly prolong incretin hormone activity. These medications operate through entirely separate pathways, with sulphonylureas acting on pancreatic beta cell potassium channels and incretins working through distinct receptor-mediated mechanisms. Understanding these differences is essential for safe and effective diabetes management.

Understanding Tolbutamide and Incretin Hormones

Tolbutamide is a first-generation sulphonylurea that was historically used in the management of type 2 diabetes mellitus. It belongs to a class of oral hypoglycaemic agents that work primarily by stimulating insulin secretion from pancreatic beta cells. Tolbutamide is not routinely marketed in the UK and does not appear in the current British National Formulary (BNF). In UK clinical practice, gliclazide is the most commonly prescribed sulphonylurea due to its more favourable pharmacokinetic profile and once- or twice-daily dosing.

Incretin hormones are naturally occurring peptides produced by the gastrointestinal tract in response to food intake. The two principal incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones play a crucial role in glucose homeostasis by enhancing insulin secretion in a glucose-dependent manner, suppressing glucagon release, slowing gastric emptying, and promoting satiety. Under normal physiological conditions, incretin hormones are rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4), resulting in a half-life of only a few minutes.

The incretin effect—the proportion of postprandial insulin secretion attributable to incretin hormones—is substantially reduced in people with type 2 diabetes, contributing to inadequate glycaemic control. Understanding the distinct mechanisms of sulphonylureas and incretin hormones is essential when considering their potential interactions and combined therapeutic use. There is no established pharmacological mechanism by which sulphonylureas, including tolbutamide, directly increase the duration of action of incretin hormones. The two systems operate through entirely different pathways: sulphonylureas act on ATP-sensitive potassium channels in beta cells, whilst incretin-based therapies either mimic GLP-1 or inhibit DPP-4 to prolong endogenous incretin activity. Only DPP-4 inhibitors and GLP-1 receptor agonists modulate incretin pathways; sulphonylureas do not.

How Sulphonylureas Work in Type 2 Diabetes

Sulphonylureas exert their glucose-lowering effect through a well-characterised mechanism involving pancreatic beta cells. These drugs bind to specific sulphonylurea receptors (SUR1) on the surface of beta cells, which are components of ATP-sensitive potassium channels. This binding causes closure of these potassium channels, leading to depolarisation of the cell membrane. The resulting depolarisation opens voltage-gated calcium channels, allowing calcium influx into the cell. The increased intracellular calcium concentration triggers the exocytosis of insulin-containing granules, thereby increasing insulin secretion into the bloodstream.

Unlike incretin-based therapies, the insulin-stimulating effect of sulphonylureas is not glucose-dependent, meaning they can promote insulin release even when blood glucose levels are normal or low. This characteristic increases the risk of hypoglycaemia, particularly if meals are delayed or skipped, or if the dose is excessive. Gliclazide, the most commonly used sulphonylurea in the UK, is typically administered once or twice daily with meals.

Sulphonylureas are metabolised primarily in the liver and excreted by the kidneys. Common adverse effects include hypoglycaemia, weight gain, gastrointestinal disturbances, and rarely, skin reactions or haematological abnormalities. According to NICE guideline NG28 (Type 2 diabetes in adults: management), a sulphonylurea may be considered as second-line therapy when metformin is contraindicated or not tolerated, though other agents—including DPP-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists—are often preferred, particularly in people with established cardiovascular or renal disease.

Patient safety advice: Individuals taking a sulphonylurea should be educated about recognising and managing hypoglycaemia symptoms (tremor, sweating, confusion, palpitations). They should carry fast-acting carbohydrates and seek medical attention if experiencing frequent hypoglycaemic episodes or if blood glucose falls below 4 mmol/L repeatedly. Suspected side effects should be reported via the MHRA Yellow Card Scheme at https://yellowcard.mhra.gov.uk.

Incretin-Based Therapies and Their Mechanism of Action

Incretin-based therapies represent a significant advancement in type 2 diabetes management and work by either mimicking or prolonging the action of endogenous incretin hormones. There are two main classes: GLP-1 receptor agonists (such as exenatide, liraglutide, semaglutide, and dulaglutide) and DPP-4 inhibitors (including sitagliptin, vildagliptin, saxagliptin, linagliptin, and alogliptin).

GLP-1 receptor agonists are synthetic analogues or modified versions of human GLP-1 that resist degradation by DPP-4 enzyme, thereby achieving prolonged duration of action ranging from hours to a week, depending on the formulation. These agents bind to GLP-1 receptors on pancreatic beta cells, stimulating insulin secretion only when glucose levels are elevated (glucose-dependent action). They also suppress glucagon secretion from alpha cells, slow gastric emptying, and act on central nervous system pathways to reduce appetite and promote weight loss. Certain GLP-1 receptor agonists—including liraglutide, subcutaneous semaglutide, and dulaglutide—have demonstrated cardiovascular outcome benefits in clinical trials and are recommended by NICE for people with type 2 diabetes and established cardiovascular disease.

DPP-4 inhibitors work by blocking the DPP-4 enzyme responsible for rapidly degrading endogenous GLP-1 and GIP. By inhibiting this enzyme, these medications increase the circulating levels and duration of action of naturally produced incretin hormones. This results in enhanced glucose-dependent insulin secretion and reduced glucagon levels. DPP-4 inhibitors are generally weight-neutral and have not demonstrated cardiovascular or renal outcome benefits in major clinical trials, unlike certain GLP-1 receptor agonists and SGLT2 inhibitors.

Both incretin-based classes offer advantages over traditional sulphonylureas: they carry minimal hypoglycaemia risk when used as monotherapy (due to glucose-dependent action), and GLP-1 receptor agonists promote weight loss rather than weight gain. According to NICE guideline NG28, incretin-based therapies are recommended at various stages of the type 2 diabetes treatment pathway. For many people with established cardiovascular disease, heart failure, or chronic kidney disease, SGLT2 inhibitors or specific GLP-1 receptor agonists with proven cardiovascular benefit are now prioritised.

Combining Sulphonylureas with Incretin-Based Medications

The question of whether tolbutamide or other sulphonylureas increase the duration of action of incretins requires careful consideration of pharmacological evidence. There is no established mechanism or clinical evidence demonstrating that sulphonylureas directly prolong incretin hormone activity. These medications operate through entirely separate pathways: sulphonylureas act directly on beta cell potassium channels, whilst incretins work through G-protein coupled receptors and intracellular signalling cascades.

Combination therapy involving a sulphonylurea and an incretin-based medication is sometimes employed in clinical practice. According to NICE guideline NG28, a DPP-4 inhibitor or GLP-1 receptor agonist may be added to existing sulphonylurea therapy if further glycaemic control is needed. When such combinations are used, the dose of the sulphonylurea should be reviewed and may need reduction to minimise hypoglycaemia risk, as both agents enhance insulin secretion (albeit through different mechanisms). The electronic Medicines Compendium (eMC) Summaries of Product Characteristics (SmPCs) for DPP-4 inhibitors (e.g., sitagliptin, linagliptin) and GLP-1 receptor agonists (e.g., liraglutide, semaglutide, exenatide) advise sulphonylurea dose reduction when these agents are combined, due to increased hypoglycaemia risk. DPP-4 inhibitors and GLP-1 receptor agonists should not be prescribed together, as they act on the same incretin pathway.

Important considerations when combining these therapies include:

• Increased hypoglycaemia risk: The glucose-independent action of sulphonylureas combined with enhanced incretin activity may increase hypoglycaemia frequency

• Dose adjustments: Sulphonylurea doses typically require reduction when adding incretin therapy; some patients may be able to discontinue the sulphonylurea if hypoglycaemia or weight gain occur

• Monitoring requirements: More frequent blood glucose monitoring is advisable during treatment initiation and dose adjustment

• Alternative approaches: Current NICE guidance allows for combinations but also supports consideration of stopping the sulphonylurea and switching to an alternative agent, particularly given the weight and potential cardiovascular benefits of certain newer therapies

Patients should contact their GP or diabetes specialist if experiencing recurrent hypoglycaemia (more than one episode per week), unexplained weight changes, or persistent hyperglycaemia despite combination therapy. For severe or prolonged hypoglycaemia (blood glucose below 4 mmol/L that does not respond to treatment, or loss of consciousness), urgent medical help should be sought. Any medication adjustments should be made under medical supervision, and patients should never alter doses independently.

Frequently Asked Questions